Molecular structure of JAK Inhibitor I, CAS Number: 457081-03-7
JAK Inhibitor I (CAS 457081-03-7)
See product citations (59)
Alternate Names:
Pyridone 6; 2-(1,1-Dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-7-one
Application:
JAK Inhibitor I is an inhibitor of JAK1, JAK2, and JAK3
CAS Number:
457081-03-7
Purity:
≥98%
Molecular Weight:
309.34
Molecular Formula:
C18H16FN3O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
JAK Inhibitor I is a potent, reversible, cell-permeable, and ATP-competitive inhibitor of JAK1, JAK2, and JAK3. Primary target: murine JAK1. JAK1 (Janus kinase 1), JAK2 and JAK3 belong to the family of non-receptor janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of STAT transcription factors to cytokine receptor-associated JAK1, JAK2 and JAK3.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
JAK Inhibitor I (CAS 457081-03-7) References
- TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. | Taura, M., et al. 2010. Cancer Sci. 101: 1610-7. PMID: 20367642
- Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. | Chrencik, JE., et al. 2010. J Mol Biol. 400: 413-33. PMID: 20478313
- Interleukin-4 up-regulates 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in human lung cancer cells. | Chi, X. and Tai, HH. 2010. Exp Cell Res. 316: 2251-9. PMID: 20632471
- Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma. | Matsunaga, Y., et al. 2011. Biochem Biophys Res Commun. 404: 261-7. PMID: 21111712
- Pyridone 6, a pan-JAK inhibitor, ameliorates allergic skin inflammation of NC/Nga mice via suppression of Th2 and enhancement of Th17. | Nakagawa, R., et al. 2011. J Immunol. 187: 4611-20. PMID: 21957150
- The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction. | Sayoc-Becerra, A., et al. 2020. Inflamm Bowel Dis. 26: 407-422. PMID: 31751457
- Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis. | Phan, K., et al. 2022. J Dermatolog Treat. 33: 173-177. PMID: 32096671
- Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis. | Keenan, C., et al. 2021. Front Immunol. 12: 614704. PMID: 33664745
- JAK-inhibitors for dermatomyositis: A concise literature review. | Paudyal, A., et al. 2021. Dermatol Ther. 34: e14939. PMID: 33713527
- The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis. | Alves, C., et al. 2022. J Clin Rheumatol. 28: e407-e414. PMID: 33902098
- Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. | Wood, H., et al. 2022. Int J Dermatol. 61: 746-754. PMID: 34423443
- Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications. | Shalabi, MMK., et al. 2022. Skin Therapy Lett. 27: 4-9. PMID: 35081305
- Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review. | McGaugh, S., et al. 2022. Dermatol Ther. 35: e15437. PMID: 35278019
- Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective. | Heinz, KC., et al. 2022. J Med Econ. 25: 491-502. PMID: 35350959
- The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. | Mascarenhas, JO. and Verstovsek, S. 2022. Cancer. 128: 2717-2727. PMID: 35385124
Inhibitor of:
β-defensin 21, β-defensin 22, β-defensin 26, γPAK, 2010002M12Rik, C-MIP, CD160, CD200R4, CRLF1, DDX60, EG216818, EG625464, F630003A18Rik, GBP3, GBP7, GFOD2, hCG_1657980, Helios, IF3, IFIT3, IFITM10, IFITM5, IFN-α/βRβ, IFN-α7, IFN-α8, IFN-γRβ, IFN-κ, IFN-τ, IIGP1B, IL-17, IL-26, IL-27Rα, IL-28, IRF-8, ISG43, JAK, JAK1, JAK2, JAK3, JAKMIP2, KRTAP5-1, LIF, LRP1, Ly-49U, Ly-6A/E, MIP-3α, MOSPD2, Myeloid lineage, NKG2-I, Olfr483, Olfr559, Olfr56, Olfr875, OTTMUSG00000011262, OTTMUSG00000016781, OTTMUSG00000016783, plexin-A1, REG IIIα, Reg IIIγ, SOCS-3, SOCS-4, SOCS-6, Stat1, SUMO-4, T Cell, TCL-6, TLR9, TRIM32, Tyk, WDR54, ZBTB42, and ZCCHC3.Activator of:
Anamorsin, AOS-1, Btnl6, CIS, Cryptosporidium parvum, D6Mm5e, EG210155, FKHRL1, GRB7, I830012O16Rik, IFN-α6, IFRG15, IL-10Rβ, IL-13, ISG20, MALL, MAML3, NF90, Olfr394, OTTMUSG00000011275, OTTMUSG00000016644, SEMA4B, STAM, Stat4, UBE1L2, and WDR87.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JAK Inhibitor I, 500 µg | sc-204021 | 500 µg | $156.00 | |||
JAK Inhibitor I, 1 mg | sc-204021A | 1 mg | $339.00 |